share_log

Ascendiant Capital Maintains Buy on Biolase, Lowers Price Target to $4

Moomoo 24/7 ·  Apr 1 05:40

Ascendiant Capital analyst Edward Woo maintains Biolase (NASDAQ:BIOL) with a Buy and lowers the price target from $15 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment